| Species | Human |
| Product Type | iPSC-derived Organoid |
| Quality Control | Negative for mycoplasma, bacteria, yeast, and fungi. |
| Tissue | Lung |
| Disease | Fibrosis(IPF), Infection Respiratory and ENT Disease |
| Generation Process | Lung organoids derived from induced pluripotent stem cells (iPSCs) recapitulate early developmental processes through stepwise differentiation into mature lung cell types and structures. These scalable and customizable models represent diverse genetic backgrounds and can be adapted to model various environmental conditions, making them powerful platforms for long-term studies, high-throughput drug screening, and regenerative medicine research. |
| Organoid Characterization | These lung organoids faithfully replicate the structural features of human lung tissue, notably including alveolar structures. Their cellular composition encompasses multiple lineages, type I and II alveolar epithelial cells, ciliated cells, and secretory cells, thereby preserving the functional diversity of native lung tissue within a consistent experimental system. |
| Applications | Generated through refined differentiation techniques, these organoids provide consistent cell populations and developmental maturity, supporting reproducible results across discovery and translational research stages. |
| Storage | Liquid Nitrogen |
| Shipping Information | Dry Ice |
For preclinical research and development use only; not intended for therapeutic or other applications.
Alfa Cytology is a preclinical research service provider specializing in tumor organoid development. We provide one-stop services that include tailored 3D cancer models, organoid-based research services, and related products to accelerate the discovery and development of cancer therapeutics.
Copyright © 2026 Alfa Cytology. All rights reserved.